STOCK TITAN

Co-Diagnostics, Inc. to Host Booth at the 2024 UHCA/UCAL Fall Convention & Expo on Oct 2-3

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

Co-Diagnostics, Inc. (Nasdaq-CM: CODX) has announced its participation in the Utah Health Care Association/Utah Center for Assisted Living (UHCA/UCAL) Convention & Expo on October 2-3, 2024. The event will take place at the Mountain America Expo Center in Sandy, Utah.

The company will host Booth 300, showcasing its upcoming Co-Dx PCR platform, including a menu of at-home and point-of-care tests in development. The convention caters to executive leadership, administrators, corporate personnel, owners, and Directors of Nursing for skilled nursing, assisted living, and intermediate care facilities.

Interested parties are invited to visit Co-Diagnostics' booth to learn more about their diagnostic products and their applications in the healthcare sector. It's important to note that the Co-Dx PCR platform, including associated tests and software, is currently under review by the FDA and other regulatory bodies and is not yet available for sale.

Co-Diagnostics, Inc. (Nasdaq-CM: CODX) ha annunciato la sua partecipazione alla Convenzione & Expo dell'Utah Health Care Association/Utah Center for Assisted Living (UHCA/UCAL) che si svolgerà il 2-3 ottobre 2024. L'evento avrà luogo presso il Mountain America Expo Center a Sandy, Utah.

L'azienda ospiterà il Padiglione 300, dove sarà presentata la sua prossima piattaforma Co-Dx PCR, compresa una gamma di test in fase di sviluppo per uso domestico e point-of-care. La convenzione è rivolta a leader esecutivi, amministratori, personale aziendale, proprietari e Direttori di Nursing per strutture di assistenza esperta, vita assistita e cure intermedie.

Le parti interessate sono invitate a visitare lo stand di Co-Diagnostics per conoscere meglio i loro prodotti diagnostici e le loro applicazioni nel settore sanitario. È importante notare che la piattaforma Co-Dx PCR, compresi i test e il software associati, è attualmente in fase di revisione da parte della FDA e di altri organismi regolatori e non è ancora disponibile per la vendita.

Co-Diagnostics, Inc. (Nasdaq-CM: CODX) ha anunciado su participación en la Convención & Expo de la Asociación de Salud de Utah/Centro de Vida Asistida de Utah (UHCA/UCAL) que se llevará a cabo el 2-3 de octubre de 2024. El evento tendrá lugar en el Mountain America Expo Center en Sandy, Utah.

La compañía contará con el Stand 300, donde mostrará su próxima plataforma Co-Dx PCR, que incluye un menú de pruebas en desarrollo para uso en casa y en el punto de atención. La convención está dirigida a líderes ejecutivos, administradores, personal corporativo, propietarios y Directores de Enfermería para centros de atención especializada, vida asistida y cuidados intermedios.

Se invita a las partes interesadas a visitar el stand de Co-Diagnostics para aprender más sobre sus productos de diagnóstico y sus aplicaciones en el sector de la salud. Es importante señalar que la plataforma Co-Dx PCR, incluidos los tests y el software asociados, está actualmente en revisión por la FDA y otros organismos reguladores y aún no está disponible para la venta.

Co-Diagnostics, Inc. (Nasdaq-CM: CODX)는 유타 건강 관리 협회/유타 보조 생활 센터 (UHCA/UCAL) 컨벤션 및 엑스포2024년 10월 2-3일에 참여한다고 발표했습니다. 이 행사는 유타주 샌디에 위치한 마운틴 아메리카 엑스포 센터에서 개최됩니다.

회사는 부스 300에서 자사의 차기 Co-Dx PCR 플랫폼을 선보이며, 여기에는 개발 중인 가정용 및 현장 테스트 menu가 포함됩니다. 이 컨벤션은 숙련된 간호, 보조 생활 및 중간 치료 시설의 경영 리더, 관리자를 포함한 관계자들에 초점을 맞추고 있습니다.

관심 있는 분들은 Co-Diagnostics의 부스를 방문하여 이들의 진단 제품과 의료 분야에서의 응용에 대해 더 알아볼 수 있습니다. Co-Dx PCR 플랫폼 및 관련 테스트와 소프트웨어는 현재 FDA 및 기타 규제 기관의 검토 중이며, 아직 판매되지 않습니다.

Co-Diagnostics, Inc. (Nasdaq-CM: CODX) a annoncé sa participation à la Convention & Expo de l'Utah Health Care Association/Centre pour la Vie Assistée de l'Utah (UHCA/UCAL) qui se déroulera les 2 et 3 octobre 2024. L'événement aura lieu au Mountain America Expo Center à Sandy, Utah.

L'entreprise tiendra le Stand 300, où elle présentera sa prochaine plateforme Co-Dx PCR, comprenant un éventail de tests à domicile et de tests sur site en cours de développement. La convention s'adresse aux dirigeants, administrateurs, personnel d'entreprise, propriétaires et Directeurs des Soins pour les établissements de soins qualifiés, de vie assistée et de soins intermédiaires.

Les parties intéressées sont invitées à visiter le stand de Co-Diagnostics pour en savoir plus sur leurs produits diagnostiques et leurs applications dans le secteur de la santé. Il est important de noter que la plateforme Co-Dx PCR, ainsi que les tests et logiciels associés, sont actuellement en cours d'examen par la FDA et d'autres organismes de réglementation et ne sont pas encore disponibles à la vente.

Co-Diagnostics, Inc. (Nasdaq-CM: CODX) hat seine Teilnahme an der Utah Health Care Association/Utah Center for Assisted Living (UHCA/UCAL) Convention & Expo am 2.-3. Oktober 2024 bekannt gegeben. Die Veranstaltung findet im Mountain America Expo Center in Sandy, Utah, statt.

Das Unternehmen wird am Stand 300 vertreten sein und seine bevorstehende Co-Dx PCR-Plattform vorstellen, die eine Auswahl von Tests für zu Hause und Point-of-Care, die sich in der Entwicklung befinden, umfasst. Die Konferenz richtet sich an Führungskräfte, Administratoren, Unternehmensmitarbeiter, Eigentümer sowie Direktoren der Pflege für Fachpflegeeinrichtungen, betreutes Wohnen und intermediäre Pflegeeinrichtungen.

Interessierte Parteien sind eingeladen, den Stand von Co-Diagnostics zu besuchen, um mehr über ihre diagnostischen Produkte und deren Anwendungen im Gesundheitswesen zu erfahren. Es ist wichtig zu beachten, dass die Co-Dx PCR-Plattform, einschließlich der dazugehörigen Tests und Software, derzeit von der FDA und anderen Regulierungsbehörden überprüft wird und noch nicht zum Verkauf angeboten werden kann.

Positive
  • None.
Negative
  • None.

SALT LAKE CITY, Oct. 2, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Co-Diagnostics will be hosting a booth at the Utah Health Care Association/Utah Center for Assisted Living (UHCA/UCAL) Convention & Expo at the Mountain America Expo Center in Sandy, Utah on October 2-3, 2024.

The UHCA/UCAL Convention includes sessions and events for executive leadership, administrators, corporate personnel, owners, and Directors of Nursing for skilled nursing, assisted living and intermediate care facilities, and will include an expo for companies to exhibit their products and services relevant to these industries. The Co-Dx™ booth will showcase the Company's upcoming Co-Dx PCR platform*, including the menu of at-home and point-of-care tests in development.

More information about the convention, including registration details and exhibition times, can be found here. Parties interested in learning more about the Company's diagnostic products and how they can be utilized in this sector are invited to visit Booth 300.

*The Co-Dx PCR platform (including the Co-Dx PCR Home™, Co-Dx PCR Pro™, mobile app, and all associated tests and software) is subject to review by the FDA and/or other regulatory bodies and is not available for sale. The Co-Dx PCR Pro instrument and Co-Dx COVID-19 Test are currently under review by the FDA.

About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform and to locate genetic markers for use in applications other than infectious disease.

Forward-Looking Statements:
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA) that are subject to a number of risks and uncertainties. Forward-looking statements can be identified by words such as "believes," "expects," "estimates," "intends," "may," "plans," "will" and similar expressions, or the negative of these words. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. Forward-looking statements in this release include statements regarding our preparation for introducing a new PCR diagnostic platform designed for at-home and point-of-care use that would be relevant to skilled nursing, assisted living, and intermediate care facilities.  Actual results may differ materially from those contemplated or anticipated by such forward-looking statements. Readers of this press release are cautioned not to place undue reliance on any forward-looking statements. There can be no assurance that any of the anticipated results will occur on a timely basis or at all due to certain risks and uncertainties, a discussion of which can be found in our Risk Factors disclosure in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission (SEC) on March 14, 2024, and in our other filings with the SEC. The Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/co-diagnostics-inc-to-host-booth-at-the-2024-uhcaucal-fall-convention--expo-on-oct-2-3-302265287.html

SOURCE Co-Diagnostics

FAQ

When and where is Co-Diagnostics (CODX) participating in the UHCA/UCAL Convention & Expo?

Co-Diagnostics (CODX) is participating in the UHCA/UCAL Convention & Expo on October 2-3, 2024, at the Mountain America Expo Center in Sandy, Utah.

What will Co-Diagnostics (CODX) be showcasing at the UHCA/UCAL Convention & Expo?

Co-Diagnostics (CODX) will be showcasing their upcoming Co-Dx PCR platform, including a menu of at-home and point-of-care tests in development, at Booth 300 during the expo.

Is the Co-Dx PCR platform by Co-Diagnostics (CODX) currently available for sale?

No, the Co-Dx PCR platform, including associated tests and software, is currently under review by the FDA and other regulatory bodies and is not yet available for sale.

Who is the target audience for the UHCA/UCAL Convention where Co-Diagnostics (CODX) is exhibiting?

The convention targets executive leadership, administrators, corporate personnel, owners, and Directors of Nursing for skilled nursing, assisted living, and intermediate care facilities.

Co-Diagnostics, Inc.

NASDAQ:CODX

CODX Rankings

CODX Latest News

CODX Stock Data

33.21M
30.21M
5.4%
14.01%
0.65%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States of America
SALT LAKE CITY